Activation of the MAPK network provides a survival advantage during the course of COVID-19-induced sepsis: a real-world evidence analysis of a multicenter COVID-19 Sepsis Cohort.
COVID-19
ERK
MAPK
MEK
PLA
RAF
Sepsis
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
13
02
2024
accepted:
13
06
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
There is evidence that lower activity of the RAF/MEK/ERK network is associated with positive outcomes in mild and moderate courses of COVID-19. The effect of this cascade in COVID-19 sepsis is still undetermined. Therefore, we tested the hypothesis that activity of the RAF/MEK/ERK network in COVID-19-induced sepsis is associated with an impact on 30-day survival. We used biomaterial from 81 prospectively recruited patients from the multicentric CovidDataNet.NRW-study cohort (German clinical trial registry: DRKS00026184) with their collected medical history, vital signs, laboratory parameters, microbiological findings and patient outcome. ERK activity was measured by evaluating ERK phosphorylation using a Proximity Ligation Assay. An increased ERK activity at 4 days after diagnosis of COVID-19-induced sepsis was associated with a more than threefold increased chance of survival in an adjusted Cox regression model. ERK activity was independent of other confounders such as Charlson Comorbidity Index or SOFA score (HR 0.28, 95% CI 0.10-0.84, p = 0.02). High activity of the RAF/MEK/ERK network during the course of COVID-19 sepsis is a protective factor and may indicate recovery of the immune system. Further studies are needed to confirm these results.
Identifiants
pubmed: 38896372
doi: 10.1007/s15010-024-02325-7
pii: 10.1007/s15010-024-02325-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Maha Bazzi
(M)
Lars Bergmann
(L)
Alexander von Busch
(A)
Stefan F Ehrentraut
(SF)
Martin Eisennacher
(M)
Sai Spoorti Ramesh
(SS)
Helge Haberl
(H)
Melanie Meersch-Dini
(M)
Katrin Marcus
(K)
Katharina Rump
(K)
Jens-Christian Schewe
(JC)
Jennifer Orlowski
(J)
Britta Marco
(B)
Matthias Unterberg
(M)
Daniel Kühn
(D)
Alexander Wolf
(A)
Birgit Zuelch
(B)
Informations de copyright
© 2024. The Author(s).
Références
Zhu N, et al. A Novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
doi: 10.1056/NEJMoa2001017
pubmed: 31978945
pmcid: 7092803
Ma Q, et al. Global percentage of asymptomatic SARS-CoV-2 Infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw Open. 2021;4: e2137257.
doi: 10.1001/jamanetworkopen.2021.37257
pubmed: 34905008
pmcid: 8672238
Rodebaugh TL, et al. Acute symptoms of mild to moderate COVID-19 are highly heterogeneous across individuals and over time. Open Forum Infect Dis. 2021;8:ofab090.
doi: 10.1093/ofid/ofab090
pubmed: 33796601
pmcid: 7989225
Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
pmcid: 7270627
Collaborators C-EM. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet. 2022;399:1513–36.
doi: 10.1016/S0140-6736(21)02796-3
Ramos-Casals M, Brito-Zeron P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17:315–32.
doi: 10.1038/s41584-021-00608-z
pubmed: 33903743
pmcid: 8072739
Seymour CW, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:762–74.
doi: 10.1001/jama.2016.0288
pubmed: 26903335
pmcid: 5433435
Rex DAB, et al. SARS-CoV-2 signaling pathway map: a functional landscape of molecular mechanisms in COVID-19. J Cell Commun Signal. 2021;15:601–8.
doi: 10.1007/s12079-021-00632-4
pubmed: 34181169
pmcid: 8237035
Schenz J, et al. Increased prevalence of clonal hematopoiesis of indeterminate potential in hospitalized patients with COVID-19. Front Immunol. 2022;13: 968778.
doi: 10.3389/fimmu.2022.968778
pubmed: 36311800
pmcid: 9614713
Preugschas HF, et al. Late activation of the Raf/MEK/ERK pathway is required for translocation of the respiratory syncytial virus F protein to the plasma membrane and efficient viral replication. Cell Microbiol. 2019;21: e12955.
doi: 10.1111/cmi.12955
pubmed: 30223301
Zhang Q, et al. Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway. J Virol. 2012;86:1544–54.
doi: 10.1128/JVI.00688-11
pubmed: 22114332
pmcid: 3264379
Pleschka S, et al. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol. 2001;3:301–5.
doi: 10.1038/35060098
pubmed: 11231581
Bonjardim CA. Viral exploitation of the MEK/ERK pathway—a tale of vaccinia virus and other viruses. Virology. 2017;507:267–75.
doi: 10.1016/j.virol.2016.12.011
pubmed: 28526201
Schreiber A, et al. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. Cell Mol Life Sci. 2022;79:65.
doi: 10.1007/s00018-021-04085-1
pubmed: 35013790
pmcid: 8747446
Haasbach E, et al. The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo. Antiviral Res. 2017;142:178–84.
doi: 10.1016/j.antiviral.2017.03.024
pubmed: 28377100
Ludwig S, Pleschka S, Planz O. MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases. Curr Opin Virol. 2023;59: 101304.
doi: 10.1016/j.coviro.2023.101304
pubmed: 36841033
pmcid: 10091867
Cusato J, et al. COVID-19: a possible contribution of the MAPK pathway. Biomedicines. 2023;11:1459.
doi: 10.3390/biomedicines11051459
pubmed: 37239131
pmcid: 10216575
Montazersaheb S, et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 2022;19:92.
doi: 10.1186/s12985-022-01814-1
pubmed: 35619180
pmcid: 9134144
Xie J, et al. Inhibition of MEK signaling prevents SARS-CoV2-induced lung damage and improves the survival of infected mice. J Med Virol. 2022;94:6097–102.
doi: 10.1002/jmv.28094
pubmed: 36030555
pmcid: 9538266
Forsyth CB, et al. The SARS-CoV-2 S1 spike protein promotes MAPK and NF-kB activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells. Microorganisms. 2022;10:1996.
doi: 10.3390/microorganisms10101996
pubmed: 36296272
pmcid: 9607240
Klaesson A, et al. Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes. Sci Rep. 2018;8:5400.
doi: 10.1038/s41598-018-23582-1
pubmed: 29599435
pmcid: 5876389
Unterberg M, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. 2023;27:417.
doi: 10.1186/s13054-023-04713-1
pubmed: 37907989
pmcid: 10619294
Hughes CS, et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc. 2019;14:68–85.
doi: 10.1038/s41596-018-0082-x
pubmed: 30464214
Hotchkiss RS, et al. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 2009;15:496–7.
doi: 10.1038/nm0509-496
pubmed: 19424209
pmcid: 3786779
Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13:679–92.
doi: 10.1038/nri3495
pubmed: 23954936
Marjuki H, et al. Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling. J Biol Chem. 2006;281:16707–15.
doi: 10.1074/jbc.M510233200
pubmed: 16608852
Wang C, et al. HA triggers the switch from MEK1 SUMOylation to phosphorylation of the ERK pathway in influenza a virus-infected cells and facilitates its infection. Front Cell Infect Microbiol. 2017;7:27.
doi: 10.3389/fcimb.2017.00027
pubmed: 28224114
pmcid: 5293797
Yewdell J, Garcia-Sastre A. Influenza virus still surprises. Curr Opin Microbiol. 2002;5:414–8.
doi: 10.1016/S1369-5274(02)00346-6
pubmed: 12160862
Ascierto PA, Dummer R. Immunological effects of BRAF+MEK inhibition. Oncoimmunology. 2018;7: e1468955.
doi: 10.1080/2162402X.2018.1468955
pubmed: 30228935
pmcid: 6140547
Li H, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395:1517–20.
doi: 10.1016/S0140-6736(20)30920-X
pubmed: 32311318
pmcid: 7164875
Babačić H, et al. Comprehensive proteomics and meta-analysis of COVID-19 host response. Nat Commun. 2023;14:5921.
doi: 10.1038/s41467-023-41159-z
pubmed: 37739942
pmcid: 10516886
Pagani L, et al. Plasma proteomic variables related to COVID-19 severity: an untargeted nLC-MS/MS investigation. Int J Mol Sci. 2023;24:3570.
doi: 10.3390/ijms24043570
pubmed: 36834989
pmcid: 9962231
Musuuza JS, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS ONE. 2021;16: e0251170.
doi: 10.1371/journal.pone.0251170
pubmed: 33956882
pmcid: 8101968